Business Context and Reporting Period
Company: Corvus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date: November 8, 2019
Context: The filing reports updated clinical data from the Phase 1/1b trial of CPI-006 (a CD73 antagonist) as a monotherapy and in combination with ciforadenant. It also presents updated data regarding the Adenosine Gene Signature biomarker. The data was presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on clinical trial updates and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Highlights
CPI-006 Clinical Trial Results
- Patient Population: Data includes 24 patients on CPI-006 monotherapy and 16 patients on combination therapy (CPI-006 + ciforadenant). Patients had advanced, refractory disease across multiple cancer types (colorectal, renal cell, pancreatic, prostate, etc.) and had failed a median of four prior therapies.
- Pharmacokinetics and Dosing: Doses of 6 mg/kg and higher produced sustained plasma levels. Doses of 12 mg/kg and higher achieved complete and sustained occupancy of CD73 on peripheral blood lymphocytes. The 18 mg/kg dose was selected for study expansion due to complete tumor occupancy.
- Immune Response: Treatment induced B-cell differentiation into plasmablasts and memory B-cells, promoting IgM secretion and class switching to IgG. Analysis showed induction of new memory B-cell clones with frequencies up to 1%, suggesting a strong antibody immune response comparable to vaccination.
- Tumor Regression: In evaluable patients receiving 6 mg/kg or higher, tumor regression was observed in 4 of 9 patients:
- Metastatic Castration-Resistant Prostate Cancer (mCRPC): 1 of 2 patients (18.2% reduction).
- Renal Cell Carcinoma (RCC): 2 of 5 patients (7.0% and 21.3% reduction).
- Non-Small Cell Lung Cancer (NSCLC): 1 of 2 patients (5.8% reduction).
- Notable Case: A patient with metastatic prostate cancer receiving 6 mg/kg monotherapy for over 19 cycles showed tumor volume reduction and reduced bone pain.
- Safety: CPI-006 was well tolerated with no dose-limiting toxicities. Grade 1 infusion reactions occurred in 3 patients (managed with premedication). Grade 3/4 toxicities included one case of Grade 3 anemia and one case of Grade 3/4 diarrhea.
Adenosine Gene Signature Data
- Biomarker Correlation: In 32 patients with renal cell cancer, a statistically significant correlation (p=0.008) was found between a positive Adenosine Gene Signature and tumor response.
- Response Rates: Among 21 biomarker-positive patients, 17% achieved a partial response (PR), and 9 patients showed tumor regression. No responses were observed in the 11 biomarker-negative patients.
- Duration of Response: Six of 21 biomarker-positive patients had progression-free survival (PFS) exceeding 40 weeks, with a plateau on the survival curve. All long-term responders were biomarker-positive, including four who had failed prior anti-PD(L)-1 therapies.
- Mechanism: CPI-006 blocks CD73, preserving AMP levels which induce gene expression changes similar to the Adenosine Gene Signature. The combination with ciforadenant (an A2A receptor antagonist) is suggested to more effectively block immunosuppressive signaling.
Guidance, Outlook, and Risks
Outlook: The Company selected the 18 mg/kg dose for continued expansion of the study. Management believes the combination of CPI-006 and ciforadenant could be a more effective strategy to block immunosuppressive effects.
Risks and Forward-Looking Statements: The filing includes standard forward-looking statements regarding the potential safety and efficacy of CPI-006 and ciforadenant, the ability to advance clinical trials, and the utility of the biomarker. Management notes substantial risks and uncertainties that could cause actual results to differ from expectations, referencing the Company's Form 10-Q for the quarter ended September 30, 2019, for a detailed risk description.
Investor Verification Checklist
- Verify the full safety profile and long-term toxicity data in the complete clinical trial report (Exhibit 99.1).
- Confirm the specific criteria used to define "tumor regression" in the 4 of 9 patients, as some reductions did not meet RECIST criteria for Partial Response.
- Review the detailed methodology for the Adenosine Gene Signature biomarker assay to assess reproducibility.
- Check the Company's most recent Form 10-Q (filed October 29, 2019) for current cash runway and liquidity status, as this 8-K does not contain financial data.
- Monitor upcoming presentations or filings regarding the expansion cohort design and enrollment timelines.